A big ‘Thank you’ to our partners
The GDNF Participant Group exists to ensure that patient voices are heard in the quest for a cure for Parkinson’s. We are an entirely voluntary group made up of the people who participated in the Bristol trial, their families and friends.A group of strangers who were brought together by their overwhelming desire to destroy Parkinson’s now and for future generations.
We firmly believe that it is only by amalgamating the knowledge of science and the experience of patients that progress can be made towards successful treatments with clinical trials that prioritise and care for the welfare of the participants.
We are keen to form partnerships with like minded organisations and thank the following for their support :-
Pioneering treatments. Accelerating cures. Saving Lives.
We focus on making sure that the most promising research in neuroscience makes it out of the lab and to the patient. All too often great research doesn’t get translated into new treatments to benefit those who need them most.
Formerly The Cure Parkinson’s Trust
A diagnosis of Parkinson’s is life changing. Our Information Hub provides resources recommended to us by people living with Parkinson’s to help you live well with Parkinson’s and discover how you can get involved with trials and surveys.
Improving life for everyone affected by Parkinson’s. Together we’ll find a cure.
We’re the Parkinson’s charity that drives better care, treatments and quality of life. Because we’re here, no one has to face Parkinson’s alone.
Face 2 Face
Non-Profit Community Interest Company.
Face2Face Parkinson’s C.I.C is a not for profit company As the name suggests we can meet people face2face at our surgeries or at their own homes. And if we can’t help directly, we usually find someone who can”. Our members are encouraged to influence the services we offer so we best meet their needs. Our three directors, with over 45 years of combined experience, are highly passionate about providing personalised support to people living or working with Parkinson’s.